A γ-secretase inhibitor decreases amyloid-β production in the central nervous system

Annals of Neurology

Volumn 66, Issue 1, 2009, Pages 48-54

  Bateman, Randall J ^a   Siemers, Eric R ^b   Mawuenyega, Kwasi G ^a   Wen, Guolin ^a   Browning, Karen R ^a   Sigurdson, Wendy C ^a   Yarasheski, Kevin E ^a   Friedrich, Stuart W ^a   DeMattos, Ronald B ^a   May, Patrick C ^a   Paul, Steven M ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 13; GAMMA SECRETASE INHIBITOR; LEUCINE; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE;

ADULT; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLEARANCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOLUNTEER;

ADULT; ALANINE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; AREA UNDER CURVE; AZEPINES; CENTRAL NERVOUS SYSTEM; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; HUMANS; MALE; MIDDLE AGED; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 66749084437     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21623     Document Type: Article

References (23)

1. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003;60:1119-1122.
2. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403.
3. Skovronsky DM, Lee VMY, Trojanowski JQ. Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 2006;1:151-170.
4. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-356.
5. Golde TE, Dickson D, Hutton M. Filling the gaps in the Aβ cascade hypothesis of Alzheimer's disease. Curr Alzheimer Res 2006;3:421-430.
6. Walsh DM, Selkoe DJ. Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron 2004;44:181-193.
7. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007;8:101-112.
8. Dovey HF, John V, Anderson JP, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001;76:173-181.
9. Cirrito J, May P, O'Dell M, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 2003;23:8844-8853.
10. Best JD, Smith DW, Reilly MA, et al. The novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) reduces amyloid plaque deposition without evidence of notch-related pathology in the Tg2576 mouse. J Pharmacol Exp Ther 2007;320:552-558.
11. Imbimbo BP, Del Giudice E, Colavito D, et al. 1-(3′,4′- dichloro-2-fluoro[1,1′-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 2007;323:822-830.
12. Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007;30: 317-325.
13. Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006;66:602-604.
14. Bateman RJ, Munsell LY, Morris JC, et al. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 2006;12:856-861.
15. Bateman RJ, Munsell LY, Chen X, et al. Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates. J Am Soc Mass Spectrometry 2007;18: 997-1006.
16. Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-{beta} levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666-669.
17. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279: 12876-12882.
18. Li T, Wen H, Brayton C, et al. Moderate reduction of gamma-secretase attenuates amyloid burden and limits mechanism-based liabilities. J Neurosci 2007;27:10849-10859.
19. Hyde LA, McHugh NA, Chen J, et al. Studies to investigate the in vivo therapeutic window of the gamma-secretase inhibitor N2-[(2S)-2-(3,5- difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo[b,d] azepin-7-yl]-L-alaninamide (LY411,575) in the CRND8 mouse. J Pharmacol Exp Ther 2006;319:1133-1143.
20. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol 2005;28:126-132.
21. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980;35: 259-266.
22. Mabuchi H, Haba T, Tatami R, et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N Engl J Med 1981;305: 478-482.
23. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992;33:1569-1582.